Advances presented at EASL 2026 suggest the HBV cure landscape is moving from scientific ambition toward clinical reality, creating new opportunities and new challenges for drug developers.
Every year, EASL offers a glimpse into the future of hepatology. This year, however, felt less like a glimpse and more like an inflection point.
Across multiple presentations, discussions, and late-breaking sessions, a common theme emerged: the hepatitis B cure field is beginning to generate the clinical evidence it has been pursuing for decades. While no single therapy has solved the challenge, EASL 2026 demonstrated that several distinct scientific approaches are now producing results that could fundamentally reshape the treatment landscape.
For sponsors developing therapies in viral hepatitis, the significance extends beyond any individual dataset. The field appears to be entering a new phase—one defined not by theoretical possibilities, but by growing proof that functional cure may be achievable.
The HBV Cure Field Is Beginning to Deliver
For years, discussions around an HBV cure have largely been framed around potential. At EASL 2026, the conversation shifted noticeably toward probability.
The most talked-about presentation came from GSK, whose Phase III bepirovirsen data reinforced the view that we are entering the first meaningful evolution of HBV treatment in more than a decade. The data were widely regarded as strong, particularly given the safety profile. Few experts would argue that bepirovirsen represents the final answer to HBV cure. What it may represent, however, is the first therapy capable of changing expectations around what treatment can realistically achieve.
Importantly, the significance of the program extends beyond a single product. It validates years of investment across multiple therapeutic approaches and reinforces growing confidence that chronic HBV infection may eventually become a curable disease.
As one industry observer remarked during the conference, bepirovirsen may not be the cure, but it is likely to influence the future standard of care and raise the bar for every program that follows.
Epigenetic Silencing Emerges as a New Frontier
While GSK's data generated considerable attention, one of the most scientifically significant moments of the conference came from Tune Therapeutics.
In a late-breaking presentation, Tune reported the first clinical evidence that direct epigenetic silencing of HBV cccDNA can be achieved in patients. Presented by Dr. Ed Gane, the findings provide the first clinical proof that this mechanism can suppress HBV at its source and potentially improve long-term outcomes for patients living with chronic hepatitis B.
The implications reach far beyond viral hepatitis.
For years, epigenetic silencing has been viewed as an exciting scientific concept with broad therapeutic potential. EASL 2026 marked one of the first times the industry has seen clinical evidence supporting that promise. If future studies continue to validate the approach, its relevance could extend across multiple disease areas where durable gene regulation may offer therapeutic benefit.
Multiple Technologies Are Advancing Simultaneously
Another notable development came from Precision BioSciences, which presented data demonstrating the first clinical evidence of elimination and inactivation of HBV cccDNA in liver biopsies from treated patients.
Because cccDNA persistence remains one of the fundamental barriers to achieving cure, evidence that therapeutic intervention can directly affect this viral reservoir represents an important milestone for the field.
Taken together, the data presented by GSK, Tune Therapeutics, Precision BioSciences and others highlighted a notable shift in the HBV landscape. The field is no longer relying on a single scientific pathway. Antisense therapies, gene-editing approaches, immune modulation strategies, and epigenetic technologies are all progressing simultaneously.
That diversity of approaches is creating momentum rarely seen in viral hepatitis research and increasing confidence that meaningful breakthroughs are becoming more achievable.
Competition Is Intensifying in Hepatitis Delta Virus
Beyond HBV, hepatitis delta virus (HDV) continues to evolve into one of the most dynamic areas of hepatology drug development.
For several years, bulevirtide has dominated the conversation. Today, however, the competitive landscape is expanding rapidly. Programs such as lonafarnib, brelovitug and several emerging candidates are advancing through development, creating new treatment options and increasing competition among sponsors.
Mirum Pharmaceuticals' presentation of Phase IIb AZURE-1 data further reinforced the growing momentum in the HDV space, with pivotal readouts expected in the second half of 2026.
As the field matures, differentiation will increasingly depend not only on clinical outcomes but also on development strategy, patient recruitment capabilities, global operational execution and regulatory planning.
Metabolic Liver Disease Faces a New Reality
While viral hepatitis dominated many scientific discussions, metabolic liver disease remained a major focus throughout the congress.
Much of the conversation centered on the evolving role of GLP-1 therapies and their potential impact on MASH. Following the approval of resmetirom and the continued success of obesity and metabolic disease treatments, sponsors are now grappling with an important strategic question: how will highly effective metabolic therapies reshape the future MASH treatment landscape?
The answer remains uncertain. However, there was growing recognition throughout EASL that liver disease can no longer be viewed in isolation from the broader metabolic conditions driving disease progression.
For developers in this space, future success may depend as much on understanding the metabolic ecosystem as on targeting liver pathology itself.
AI and Omics Continue to Shape the Future
Artificial intelligence and omics technologies remained prominent themes throughout the congress, although the conversation appears to be maturing.
Rather than focusing on theoretical applications, discussions increasingly centered on practical implementation. From biomarker discovery and patient stratification to treatment optimization and clinical trial design, AI is beginning to demonstrate tangible value across both research and clinical development.
Similarly, advances in multi-omics technologies continue to deepen understanding of disease biology and support increasingly precise therapeutic approaches.
These tools are unlikely to replace scientific expertise, but they are rapidly becoming essential components of modern drug development.
What This Means for Drug Developers
The biggest takeaway from EASL 2026 is not that the HBV cure challenge has been solved. It has not.
What has changed is the level of clinical evidence supporting multiple paths toward that goal.
For years, the industry has operated on the belief that an HBV cure was scientifically possible. Today, that belief is increasingly being supported by human data. The result is a field entering a period of accelerated innovation, heightened competition and growing investor confidence.
For sponsors, the opportunities are significant—but so are the complexities. Development programs are becoming increasingly global, biomarker strategies more sophisticated, and regulatory pathways more nuanced.
The organizations most likely to succeed will be those capable of combining scientific innovation with operational excellence and deep therapeutic expertise.
If EASL 2026 demonstrated anything, it is that the future of viral hepatitis development is arriving faster than many anticipated. The next few years may determine which companies lead the transition from chronic disease management to the era of cure.